4SC AG – Resminostat Marketing Application Proceeding & Kinselby ...
4SC AG announced EMA's acceptance of its Letter of Intent for a Marketing Authorization Application for resminostat, with the trade name Kinselby approved. If approved, Kinselby would be the first HDAC inhibitor in Europe for CTCL, marking a significant milestone for 4SC in its commercialization efforts.
Reference News
4SC AG announced EMA's acceptance of its Letter of Intent for a Marketing Authorization Application for resminostat, with the trade name Kinselby approved. If approved, Kinselby would be the first HDAC inhibitor in Europe for CTCL, marking a significant milestone for 4SC in its commercialization efforts.
4SC AG announced EMA's acceptance of its Letter of Intent for a Marketing Authorization Application for resminostat, with the trade name Kinselby approved. Kinselby, a potential first HDAC inhibitor for CTCL in Europe, aims to enhance treatment durability and quality of life for patients.
4SC AG filed a letter of intent with the EMA for Marketing Authorization of resminostat in CTCL, aiming for submission in Q1 2024. Resminostat, an HDAC inhibitor, showed promise in prolonging progression-free survival in CTCL patients in the RESMAIN study, with detailed data expected in Q3 2023.